NCT00192218View on ClinicalTrials.gov

Study to Evaluate the Effectiveness of FluMist Vaccination in a School-Based Intervention Program

PHASE4CompletedINTERVENTIONAL
Enrollment

3,022

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

April 30, 2005

Study Completion Date

April 30, 2005

Conditions
Influenza
Interventions
BIOLOGICAL

FluMist

0.5 ml of vaccine intranasally (0.25 ml in each nostril) which contains approximately 107 TCID50 of each type

Trial Locations (2)

21201

Division of General Pediatrics, University of Maryland School of Medicine, Baltimore

98108

Division of Allergy and Infectious Diseases, University of Washington School of Medicine, Seattle

Sponsors

Lead Sponsor

MedImmune LLC
All Listed Sponsors
lead

MedImmune LLC

INDUSTRY